Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries - Candlesense
SANN Partnership

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

Pratteln, Switzerland, 19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

Related Questions

How will the GCC distribution agreement affect Santhera's revenue forecasts and earnings guidance? What is the potential market size for AGAMREE® in the GCC region and how does it compare to existing DMD treatments? What regulatory or reimbursement hurdles could impact the rollout of Vamorolone in these countries and affect the stock price?
Find similar articles on Candlesense globenewswire